‹ Screener

Nakamoto Inc.

NAKA, NAKAW · Finance Services · 696.1M shares · +20%/yr ↑ shares · EDGAR filings ↗
Net buyback after stock comp: -$219K (gross $22K, SBC $241K)

Reference price $5.79 · est. market cap ~$4.0B — last insider purchase, 2026-05-28 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)

Grade

D45

Nakamoto Inc — bitcoin-treasury firm (KindlyMD merger) with deep losses.

Strengths

Risks

Notable findings

Quarterly revenue

2025-06-30 · $408K2025-09-30 · $388K2025-12-31 · $445K2026-03-31 · $3M

Last 4 quarters · from SEC filings.

Key metrics

Operating margin
-10824.0%
Net margin
-2867.6%
Return on equity
-10.2%
Return on assets
-7.1%
Revenue growth (QoQ)
501.9%
Current ratio
1.0×
Tangible book value
$511M
Cash & investments
$58M
Stock comp / revenue
129.5%

Insider transactions · last 18 months

DateInsiderTypeSharesPrice
2026-05-28Bailey David FBuy48K$5.59
2026-05-28Bailey David FBuy7.1K$5.79
2026-05-27Bailey David FBuy26K$5.33
2026-05-27Bailey David FBuy79K$4.68
2026-05-26Bailey David FBuy32K$5.58
2026-03-12Evans Tyler MatthewGrant600K
2026-02-20Bailey David FGrant108.2M
2026-02-20Evans Tyler MatthewGrant17.8M
2026-02-20Evans Tyler MatthewGrant17.8M
2025-12-16Gendron Teresa SGrant2.6M
2025-12-16Dalton John MerrittGrant1.6M
2025-09-22Evans Tyler MatthewGrant602K
2025-09-22YUSKO MARK WGrant113K
2025-09-22McNulty Perianne BoringGrant113K
2025-09-22Blackburn Charles PhillipGrant113K
2025-09-22Weiss Eric StantonGrant113K
2025-09-22Barrera JaredGrant6.4K
2025-09-22Pickett TimothyGrant38K
2025-09-22Pickett TimothyGrant26K
2025-09-22Pickett TimothyGrant10K
2025-09-22Pickett TimothyGrant18K
2025-09-22Xethalis Gregory EliasGrant113K
2025-09-22Fabiano AmandaGrant752K
2025-09-22Fabiano AmandaGrant3.4M
2025-09-22Bailey David FGrant752K
2025-09-22Creighton Andrew JohnGrant602K
2025-08-14Evans Tyler MatthewGrant2.2M
2025-08-14Creighton Andrew JohnGrant2.2M
2025-08-14Bailey David FGrant11.2M
2025-05-12Seelhorst GaryGrant1.8K$1.61
2025-05-12Robinson Christian S.Grant1.8K$1.61
2025-05-12Powell AmyGrant1.8K$1.61
2025-05-12Pickett TimothyGrant29K$1.61

All non-derivative Form 4 activity (SEC), newest first.

Clinical trials

TrialTitlePhaseStatusPrimary completion
NCT03179501 ↗NP001, Alzheimer's Disease, and Blood Markers of Inflammation
Alzheimer Disease
PHASE1Terminated2018-07-31

Source: ClinicalTrials.gov (U.S. NIH) · active studies first.

Notable events (8-K)

DateItems
2026-06-22Auditor changeExhibitsfiling ↗
2026-06-11Debt obligationReg FDOtherExhibitsfiling ↗
2026-05-223.03Exec/director change5.03Reg FDExhibitsfiling ↗
2026-05-13ResultsExhibitsfiling ↗
2026-05-12Shareholder voteExhibitsfiling ↗
2026-05-07Material agreementExec/director changeExhibitsfiling ↗
2026-04-07Exhibitsfiling ↗
2026-03-31ResultsExhibitsfiling ↗

Recent filings

FormFiledPeriodAccession
8-K2026-06-222026-06-170001493152-26-029606 ↗
8-K2026-06-112026-06-050001493152-26-028223 ↗
8-K2026-05-222026-05-210001493152-26-025015 ↗
8-K2026-05-132026-05-130001493152-26-022786 ↗
10-Q2026-05-132026-03-310001493152-26-022777 ↗
8-K2026-05-122026-05-080001493152-26-022494 ↗
8-K2026-05-072026-05-040001493152-26-021600 ↗
8-K/A2026-04-072026-02-260001493152-26-015426 ↗
8-K2026-03-312026-03-300001493152-26-013693 ↗
10-K2026-03-302025-12-310001493152-26-013601 ↗
8-K2026-02-262026-02-200001493152-26-008131 ↗
8-K2026-02-192026-02-180001493152-26-007414 ↗